Connect your AI

CeriBell, Inc. CBLL Debt Issuance Costs

Debt Issuance Costs at other companies

Kestra Medical Technologies, Ltd. Common StockKMTS

$588.25K—

Alto NeuroscienceANRO

$0-100%

Other financials

Income statement

Revenue$26.5M+29.3%

Gross profit$23.1M+28.4%

Operating income-$20.7M-46.0%

Net income-$19.7M-54.5%

EPS (diluted)-$0.52-44.4%

Balance sheet

Cash & equivalents$45.3M-70.5%

Total debt$22.1M+1.6%

Total equity$140.8M-22.2%

Total assets$178.1M-16.6%

Cash flow

Operating cash flow-$19.3M-69.2%

CapEx$125.0K-15.5%

Free cash flow-$19.4M-68.1%

Valuation

Market cap$748.61M+15.6%

Enterprise value$725.47M+40.7%

P/S7.9×-1.2×

Profitability

Gross margin87.7%+0.5pp

Operating margin-68.3%+5.5pp

Net margin-63.5%+1.0pp

FCF margin-52%-1.4pp

Returns & leverage

Return on equity-37.5%—

Debt / equity0.2×0.0×

Current ratio10.4×-6.9×

Where this comes from

Reported directly by CeriBell, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: CeriBell, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about CeriBell, Inc.'s debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CeriBell, Inc.'s debt issuance costs?: CeriBell, Inc. (CBLL) reported debt issuance costs of $0 in Q1 2026.
What does debt issuance costs mean?: Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.